药明康德：2025年净利同比预增103%

Core Viewpoint - WuXi AppTec (603259.SH) expects a net profit of 19.151 billion yuan for the year 2025, representing a year-on-year increase of approximately 103% [1] Financial Performance - The expected basic earnings per share for the period is approximately 6.70 yuan per share, reflecting a year-on-year growth of about 104.27% [1] - The increase in net profit includes gains from the sale of partial equity in an associate company and the divestiture of certain business segments [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - WuXi AppTec is committed to meeting customer demands for empowerment, continuously expanding new capabilities, building new production capacity, and optimizing production processes to enhance operational efficiency [1] Non-Recurring Gains - The impact of non-recurring gains on the net profit attributable to shareholders mainly comes from the net gain of approximately 4.161 billion yuan from the sale of part of its stake in WuXi XDCCayman Inc. [1] - Additionally, the net gain from the sale of 100% equity in Shanghai Kangde Hongyi Medical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. is expected to be around 1.434 billion yuan [1]